SNDX Stock — Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc. (SNDX)

Updated October 16, 2026.

SNDX is a Stock. Total return is 7.4% over the past 10.6 years, 346.9 points behind SPY at 354.3%.

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapies for cancer and related diseases, with lead products including Revuforj (revumenib), a menin inhibitor for acute leukemia, and Niktimvo (axatilimab-csfr), a therapeutic antibody for chronic graft-versus-host disease. The company does not currently have an established distribution schedule. This security appeals primarily to growth-oriented investors focused on the healthcare and biotechnology sectors, as the company is in active development and commercialization phases rather than generating income for shareholders.

SNDX performance versus SPY

Price and return data through 2026-10-16.

Total return is 7.4% over the past 10.6 years, 346.9 points behind SPY at 354.3%. Over the past year its total return — price change plus distributions reinvested — is -14.3%. Its deepest 1-year drawdown was 48.7%.

SNDX key facts

Asset type

Stock

Asset class

Equity

Inception date

03/03/2016

Distribution frequency

None

Last close

$12.90 (as of 2026-10-16)

Market cap

$1,151,932,409

Average volume

2837693.0

Beta

0.424

Payout ratio

0.0%

EPS

$-2.53

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

SNDX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 48.7%.

Who may consider SNDX — and who may not

It is a weaker fit for investors who need monthly cash flow (SNDX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on SNDX

• All tickers starting with S

Tagged: Healthcare.

Frequently asked questions